The drug was approved in India in November this year and is the “first” to be approved in eight years for the management of this infection ...

Biocon, the country's largest biotech company, reported a 15% rise in fourth-quarter revenue to 746 crore, helped by a 17% rise in sales at...

NPPA has initiated a process to end the freedom enjoyed by drug makers to fix the retail price of their imported medicines.

Biocon Ltd reported a 25 percent rise in fourth-quarter profit as strong sales of its biopharmaceutical drugs helped offset muted sales at ...

The agreement includes the commercialisation of Biocon’s biosimilar versions of insulin and insulin analog products: recombinant human insu...

Wockhardt and Biocon have come under the drug price regulator National Pharmaceutical Pricing Authority (NPPA) scanner for allegedly violat...

Biotech company Biocon said it has launched the drug Abraxane, used in the treatment of breast cancer.

The new immunosuppressants for renal therapy are at least 35-40 per cent cheaper than the MNC drug prices in the similar product category.